World's Best Scientists 2026 revealed!
Frank Grünebach

Frank Grünebach

D-Index & Metrics

Immunology

D-Index
43
Citations
7398
World Ranking
4842
National Ranking
310

Overview

Frank Grünebach is affiliated with the University of Tübingen in Germany. Their research primarily falls within the field of Immunology and Microbiology, with five publications contributing to this area. Their work also intersects with subfields including Immunology and Molecular Biology.

Their research topics focus on several areas related to immune system function and pathology. These include:

  • Immune Cell Function and Interaction
  • Inflammasome and Immune Disorders
  • Immune Response and Inflammation
  • T-cell and B-cell Immunology
  • Immunodeficiency and Autoimmune Disorders

Grünebach's scholarly output includes recent papers demonstrating engagement with both clinical and molecular aspects of immunology. Notable publications are:

  • "Monocyte-derived dendritic cells display a highly activated phenotype and altered function in patients with familial Mediterranean fever," 2020, published in Clinical & Experimental Immunology
  • "Deletion of the HLA-B Gene in One of the Inherited Haplotypes in a Northern European Family," 2025, published in HLA

Frequent collaborators contributing to their research include:

  • Reinhild Klein
  • Tanja Funk
  • Alexander R. Fuchs
  • Vanessa Altdörfer
  • Stella E. Autenrieth

Their work appears in specialized venues relevant to immunology and histocompatibility, specifically Clinical & Experimental Immunology and HLA journals.

Best Publications

  • Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells.

    Susanne M. Schmidt;Kerstin Schag;Martin R. Müller;Markus M. Weck

  • Heterogeneity among human bone marrow-derived mesenchymal stem cells and neural progenitor cells

    Wichard Vogel;Frank Grünebach;Conrad A Messam;Lothar Kanz

  • Dendritic Cell Immunogenicity Is Regulated by Peroxisome Proliferator-Activated Receptor γ

    Alessio Nencioni;Frank Grünebach;Anke Zobywlaski;Claudio Denzlinger

  • Proteasome inhibitors: antitumor effects and beyond.

    A Nencioni;F Grünebach;F Patrone;A Ballestrero

  • The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.

    Peter Brossart;Anya Schneider;Patricia Dill;Theodora Schammann

  • Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses

    Julia Hilpert;Ludger Grosse-Hovest;Frank Grünebach;Corina Buechele

  • PPAR-γ agonists inhibit toll-like receptor-mediated activation of dendritic cells via the MAP kinase and NF-κB pathways

    Silke Appel;Valdete Mirakaj;Anita Bringmann;Markus M. Weck

  • Generation of Functional Human Dendritic Cells From Adherent Peripheral Blood Monocytes by CD40 Ligation in the Absence of Granulocyte-Macrophage Colony-Stimulating Factor

    Peter Brossart;Frank Grünebach;Gernot Stuhler;Volker L. Reichardt

  • Processing and presentation of HLA class I and II epitopes by dendritic cells after transfection with in vitro transcribed MUC1 RNA

    Daniela Dörfel;Silke Appel;Frank Grünebach;Markus M. Weck

  • Transfection of dendritic cells with RNA induces CD4- and CD8-mediated T cell immunity against breast carcinomas and reveals the immunodominance of presented T cell epitopes.

    Martin R. Müller;Frank Grünebach;Alessio Nencioni;Peter Brossart

  • Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.

    Silke Appel;Andreas M. Boehmler;Frank Grünebach;Martin R. Müller

  • Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity.

    Alessio Nencioni;Julia Beck;Daniela Werth;Frank Grünebach

  • Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation.

    Alessio Nencioni;Karin Schwarzenberg;Karin Schwarzenberg;Katharina M. Brauer;Katharina M. Brauer;Susanne M. Schmidt;Susanne M. Schmidt

  • Tumor Necrosis Factor α and CD40 Ligand Antagonize the Inhibitory Effects of Interleukin 10 on T-Cell Stimulatory Capacity of Dendritic Cells

    Peter Brossart;Anke Zobywalski;Frank Grünebach;Lars Behnke

  • Expression of MUC-1 Epitopes on Normal Bone Marrow: Implications for the Detection of Micrometastatic Tumor Cells

    Wolfram Brugger;Hans-Jörg Bühring;Frank Grünebach;Wichard Vogel

  • Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study

    W. Brugger;J. Hirsch;F. Grünebach;R. Repp

  • Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes.

    F Grünebach;M R Müller;A Nencioni;P Brossart

  • CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK-cell reactivity against human acute myeloid leukemia cells.

    Tina Baessler;Jean Enno Charton;Benjamin Joachim Schmiedel;Frank Grünebach

  • Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA

    Caterina Milazzo;Volker L. Reichardt;Martin R. Müller;Frank Grünebach

  • TLR ligands differentially affect uptake and presentation of cellular antigens

    Markus Michael Weck;Frank Grünebach;Daniela Werth;Christian Sinzger

  • The use of dendritic cells in cancer immunotherapy

    Alessio Nencioni;Frank Grünebach;Susanne M. Schmidt;Martin R. Müller

Frequent Co-Authors

Peter Brossart
Peter Brossart University Hospital Bonn
Lothar Kanz
Lothar Kanz University of Tübingen
Alessio Nencioni
Alessio Nencioni University of Genoa
Stefan Stevanovic
Stefan Stevanovic University of Tübingen
Hans-Georg Rammensee
Hans-Georg Rammensee University of Tübingen
Hans-Jörg Bühring
Hans-Jörg Bühring University of Tübingen
Tim H. Brümmendorf
Tim H. Brümmendorf RWTH Aachen University
Alexander Steinle
Alexander Steinle Goethe University Frankfurt
Sebastian Wesselborg
Sebastian Wesselborg University of Tübingen
Kirsten Lauber
Kirsten Lauber Ludwig-Maximilians-Universität München

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing a related healthcare degree can open diverse career opportunities. Many professionals start with nursing programs and specialize later. Accelerated programs are an excellent option for students with a non-nursing background. For example, online absn programs for non nurses provide a fast-track path to enter the nursing field, laying a strong foundation for immunology-related roles.

Once in nursing, further specialization is possible through programs like the accelerated nurse practitioner program. These intensive courses prepare nurses for advanced practice roles, which can be highly relevant for immunology practitioners focusing on patient immune health.

Certification is another crucial step for career advancement. For example, those moving from general healthcare to more specialized fields may consider an acute care np certification, emphasizing skills in managing complex, critical conditions. This can complement immunology expertise in hospital or clinical settings.

Understanding earning potential is also essential when planning your studies. According to data on how much does a dnp make, salaries vary significantly by location and specialization, making it important to research financial prospects alongside educational choices.

Best Scientists Citing Frank Grünebach

Trending Scientists

Recently Published Articles